Le Lézard
Classified in: Health, Science and technology
Subject: Conference

GlycoMimetics to Present at Three Upcoming Virtual Healthcare Investor Conferences

GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that executives from the Company plan to participate in three virtual healthcare conferences in March. More information about the presentations and panel discussions will be available on the Company's website, under the Investors tab. Details are as follows:

Cowen 41st Annual Health Care Conference
March 1 ? March 4, 2021
Eric Feldman, M.D., GlycoMimetics Vice President, Clinical Development, to participate in Leukemias Panel
Wed, March 3, 2021, 11:40 a.m. ? 12:40 p.m. (EST)
Access to the panel discussion is for registered attendees only.

H.C. Wainwright Global Life Sciences Conference
March 9 ? 10, 2021
Rachel King, GlycoMimetics CEO, to present a corporate overview
The presentation will be available on-demand, beginning at 7 a.m. ET, March 9 through March 10. Access will be provided through the Company's website (Investors section) and archived for 90 days.

33rd Annual Virtual Roth Conference
March 15 ? 17, 2021
Rachel King, GlycoMimetics CEO, to present a corporate overview
Mon, March 15, 10:00 a.m. ? 12:00 p.m. (EST) in Virtual 2 (Panel: Navigating Clinical Development in Rare Hematology & Inflammatory Disease). A link to the panel session will be available in the Investors section of the GlycoMimetics website.

About GlycoMimetics, Inc.

GlycoMimetics is a biotechnology company with a focus in hematology-oncology and a pipeline of novel glycomimetic drugs, all designed to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' drug candidate, uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2 clinical trial as a potential treatment for AML and is being evaluated across a range of patient populations including in a Company-sponsored Phase 3 trial in relapsed/refractory AML under Breakthrough Therapy Designation. Rivipansel, a pan-selectin antagonist, is being explored for use in treatment of acute VOC in sickle cell disease. GlycoMimetics has also completed a Phase 1 clinical trial with another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

These press releases may also interest you

at 09:05
Kestra Financial, an industry-leading wealth management platform, today announced the hiring of Elena Stebakov as its Vice President of Product & Platform Management. In this new role, Stebakov will bring the firm's next-generation technology vision...

at 09:05
Cigna , a global health service company, and Oscar Health, Inc. , the first health insurance company built on a full stack technology platform, today announced that Cigna + Oscar1 small business health insurance will be available to Connecticut...

at 09:05
Shakepay, a Montreal-based financial technology platform that allows Canadians to buy and sell digital currency and pay their friends, announced today that it has partnered with Marqeta, the global modern card issuing platform, to power the launch of...

at 09:05
Attivo Networks®, the industry experts in preventing identity privilege escalation and detecting lateral movement attacks, announced today that the San Francisco Business Times has selected the company for this year's Largest Greater Bay Area...

at 09:05
Upland Software, Inc. today announced it will release financial results for the first quarter after market close on Wednesday, May 5, 2021. An investor conference call will follow at 4:00 p.m. Central Time. The call can be accessed via a webcast on...

at 09:05
Redpoint Global, a leading software provider that helps brands deliver revenue-generating and personalized customer experiences, today announced new research finding that personalization is key to travel marketing. Conducted by Dynata, the survey of...

News published on 26 february 2021 at 16:35 and distributed by: